Cargando…
CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction
Despite its established inter-individual variability, sildenafil has been the subject of only a few pharmacogenetic investigations, with limited data regarding the genetic modulators of its pharmacokinetics. We conducted a pharmacogenetic substudy of patients randomized to sildenafil (n = 85) in the...
Autores principales: | de Denus, Simon, Rouleau, Jean L., Mann, Douglas L., Huggins, Gordon S., Pereira, Naveen L., Shah, Svati H., Cappola, Thomas P., Fouodjio, René, Mongrain, Ian, Dubé, Marie-Pierre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656562/ https://www.ncbi.nlm.nih.gov/pubmed/28440343 http://dx.doi.org/10.1038/tpj.2017.8 |
Ejemplares similares
-
A Pharmacogenetic Investigation of Intravenous Furosemide in Decompensated Heart Failure: A Meta-Analysis of 3 Clinical Trials
por: de Denus, Simon, et al.
Publicado: (2016) -
Sildenafil and Kidney Function in Heart Failure with Preserved Ejection Fraction
por: Edmonston, Daniel, et al.
Publicado: (2023) -
Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial
por: De Marco, Corrado, et al.
Publicado: (2021) -
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019) -
Quantitative Proteomic Analysis of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction
por: Hanff, Thomas C., et al.
Publicado: (2021)